Reported Saturday, Lilly's Triple Agonist Retatrutide Achieves 28.3% Weight Loss And 60.6% Sleep Apnea Reduction In Phase 3 TRIUMPH-1 Trial At 80 Weeks

뉴스 본문을 불러오고 있어요.

Reported Saturday, Lilly's Triple Agonist Retatrutide Achieves 28.3% Weight Loss And 60.6% Sleep Apnea Reduction In Phase 3 TRIUMPH-1 Trial At 80 Weeks | 웨이프 WAPE

Reported Saturday, Lilly's Triple Agonist Retatrutide Achieves 28.3% Weight Loss And 60.6% Sleep Apnea Reduction In Phase 3 TRIUMPH-1 Trial At 80 Weeks

기사 요약

관련 종목

댓글 —